EA202090049A1 - Поксвирусные векторы, кодирующие антигены вич, и способы их применения - Google Patents

Поксвирусные векторы, кодирующие антигены вич, и способы их применения

Info

Publication number
EA202090049A1
EA202090049A1 EA202090049A EA202090049A EA202090049A1 EA 202090049 A1 EA202090049 A1 EA 202090049A1 EA 202090049 A EA202090049 A EA 202090049A EA 202090049 A EA202090049 A EA 202090049A EA 202090049 A1 EA202090049 A1 EA 202090049A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hiv
poxvirus vectors
antigenes
ways
application
Prior art date
Application number
EA202090049A
Other languages
English (en)
Inventor
Франк Вегманн
Йоханнес Петрус Мария Лангедейк
Йером Хюбертина Хенрикус Виктор Кюстерс
Вики Бокстал
Маркус Калла
Original Assignee
Янссен Вэксинс Энд Превеншн Б.В.
Бавариан Нордик А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Вэксинс Энд Превеншн Б.В., Бавариан Нордик А/С filed Critical Янссен Вэксинс Энд Превеншн Б.В.
Publication of EA202090049A1 publication Critical patent/EA202090049A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Изобретение относится к поксвирусным векторам, кодирующим синтетический антиген оболочки ВИЧ и другие антигены ВИЧ, а также композициям, содержащим такие поксвирусные векторы, и к применению таких поксвирусных векторов в качестве вакцин для повышения иммунитета против ВИЧ. Также изобретение относится к вакцинным комбинациям, содержащим раскрытые поксвирусные векторы, аденовирусные векторы, кодирующие один или более антигенов ВИЧ, и один или более выделенных антигенных полипептидов ВИЧ, и способам применения вакцинных комбинаций для повышения иммунитета против ВИЧ.
EA202090049A 2017-06-15 2018-06-14 Поксвирусные векторы, кодирующие антигены вич, и способы их применения EA202090049A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762520079P 2017-06-15 2017-06-15
PCT/IB2018/054386 WO2018229711A1 (en) 2017-06-15 2018-06-14 Poxvirus vectors encoding hiv antigens, and methods of use thereof

Publications (1)

Publication Number Publication Date
EA202090049A1 true EA202090049A1 (ru) 2020-04-15

Family

ID=63103974

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090049A EA202090049A1 (ru) 2017-06-15 2018-06-14 Поксвирусные векторы, кодирующие антигены вич, и способы их применения

Country Status (12)

Country Link
US (2) US11229693B2 (ru)
EP (1) EP3638302B1 (ru)
JP (1) JP7272965B2 (ru)
KR (1) KR20200015759A (ru)
CN (1) CN110958887B (ru)
AU (1) AU2018283811B2 (ru)
BR (1) BR112019026126A2 (ru)
CA (1) CA3066573A1 (ru)
CO (1) CO2019014677A2 (ru)
EA (1) EA202090049A1 (ru)
MA (1) MA49397A (ru)
WO (1) WO2018229711A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
EP3518981A4 (en) 2016-10-03 2020-06-10 President and Fellows of Harvard College DELIVERING THERAPEUTIC RNAS VIA ARRDC1-MEDIATED MICROVESICLES
KR20200015759A (ko) 2017-06-15 2020-02-12 얀센 백신스 앤드 프리벤션 비.브이. Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법
WO2020237052A1 (en) 2019-05-22 2020-11-26 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
KR102636452B1 (ko) 2020-03-04 2024-02-14 주식회사 바이오앱 식물체에서 ｃｏｖｉｄ－１９ 백신용 단백질을 발현하는 재조합 벡터 및 이를 이용한 백신 조성물의 제조방법
KR102657261B1 (ko) 2020-04-03 2024-04-15 조선대학교산학협력단 Ｃｏｖｉｄ－１９ 진단을 위한 재조합 코로나－１９ 바이러스 스파이크 단백질의 생산 및 이의 용도
EP4228668A1 (en) * 2020-10-16 2023-08-23 President and Fellows of Harvard College Ww-domain-activated extracellular vesicles targeting hiv
WO2022084333A1 (en) 2020-10-20 2022-04-28 Janssen Vaccines & Prevention B.V. Hiv vaccine regimens
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US5761893A (en) 1996-10-22 1998-06-09 Lofquist Welding, Inc. Crop saving attachment for the snouts of combines
DE60014489T3 (de) 1999-05-17 2010-08-12 Crucell Holland B.V. Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US7468181B2 (en) 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
CA2384271A1 (en) 1999-09-17 2001-03-22 Joseph G. Sodroski Stabilized soluble glycoprotein trimers
IL154712A0 (en) 2000-11-23 2003-10-31 Bavarian Nordic As Modified vaccinia ankara virus variant
US20030198621A1 (en) 2001-07-05 2003-10-23 Megede Jan Zur Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
EP2345665A3 (en) 2001-12-04 2012-02-15 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
DK1418942T3 (da) 2001-12-10 2005-11-28 Bavarian Nordic As Poxvirus-holdige sammensætninger og fremgangsmåde til fremstilling deraf
JP4495588B2 (ja) 2002-04-25 2010-07-07 クルセル ホランド ベー ヴェー 安定なアデノウイルスベクターおよびその増殖方法
NZ536502A (en) * 2002-05-16 2005-10-28 Bavarian Nordic As Recombinant poxvirus expressing homologous genes inserted into the poxviral genome for inducing an immune response in a mammal
WO2004044155A2 (en) 2002-11-07 2004-05-27 Beth Israel Deaconess Medical Center MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
US7901690B2 (en) 2002-12-03 2011-03-08 University Of Massachusetts Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
WO2004087201A2 (en) 2003-03-28 2004-10-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva virus expressing modified hiv envelope, gag, and pol genes
US20070166784A1 (en) 2003-09-15 2007-07-19 Barnett Susan W Combination approaches for generating immune responses
WO2005052119A2 (en) 2003-11-19 2005-06-09 Beth Israel Deaconess Medical Center Adjuvants of immune response
LT2163260T (lt) 2004-01-23 2017-06-26 Msd Italia S.R.L. Šimpanzės adenoviruso vakcinos nešikliai
US20080274134A1 (en) 2004-06-15 2008-11-06 Norbert Schulke Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex
CA2573702C (en) 2004-07-16 2013-10-15 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Vaccine constructs and combination of vaccines designed to improve the breadth of the immune response to diverse strains and clades of hiv
WO2006026667A2 (en) 2004-08-27 2006-03-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes
AU2005293568B2 (en) 2004-10-13 2010-10-28 Beth Israel Deaconess Medical Center Inc. Improved adenoviral vectors and uses thereof
CN101072585A (zh) 2004-11-01 2007-11-14 诺华疫苗和诊断公司 产生免疫应答的组合方法
WO2007005934A2 (en) 2005-07-06 2007-01-11 University Of Maryland Biotechnology Institute Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
CN101969996A (zh) 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
CA2655934A1 (en) 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Soluble stabilized trimeric hiv env proteins and uses thereof
CA2667358A1 (en) 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
US20080279879A1 (en) 2006-11-17 2008-11-13 New York University INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE
MX362698B (es) 2007-03-02 2019-02-01 Glaxosmithkline Biologicals Sa Metodo novedoso y composiciones.
SI2340038T1 (en) 2008-10-10 2018-05-31 Children's Medical Center Corporation A biochemically stabilized HIV-1 ENV TRIMER vaccine
DK2358757T3 (da) * 2008-11-18 2019-01-02 Beth Israel Deaconess Medical Ct Inc Antivirale vacciner med forbedret cellulær immunogenicitet
WO2010060632A1 (en) 2008-11-27 2010-06-03 Bavarian Nordic A/S Promoters for recombinant viral expression
SG172935A1 (en) 2009-02-02 2011-08-29 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
US9241986B2 (en) 2010-01-04 2016-01-26 Kj Biosciences Llc DPS fusion proteins for use in vaccines and diagnostics
EP2529010B1 (en) 2010-01-28 2017-04-19 Bavarian Nordic A/S Vaccinia virus mutants containing the major genomic deletions of mva
PL2536829T3 (pl) 2010-02-15 2016-09-30 Sposób wytwarzania wektorów adenowirusowych Ad26
PT3556396T (pt) 2010-08-31 2022-07-04 Scripps Research Inst Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
US9173933B2 (en) * 2010-10-15 2015-11-03 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara influenza vaccine
EA029504B1 (ru) 2010-12-14 2018-04-30 Дзе Гавермент Оф Дзе Юнайтед Стейтс Оф Америка Эз Репрезентед Бай Дзе Секретэри Оф Дзе Департмент Оф Хелт Энд Хьюмэн Сервисиз Способ индуцирования иммунного ответа против филовирусного антигена у пациента с использованием аденовирусов серотипа 26 и серотипа 35
WO2013036791A2 (en) 2011-09-09 2013-03-14 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2766037A4 (en) 2011-10-12 2015-08-05 Scripps Research Inst HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF
US10111946B2 (en) 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
WO2014047261A1 (en) 2012-09-19 2014-03-27 Beth Israel Deaconess Medical Center, Inc. Viruses associated with immunodeficiency and enteropathy and methods using same
UA118340C2 (uk) 2012-10-28 2019-01-10 Баваріан Нордік А/С Промотор pr13.5 для стійких t-клітинних та гуморальних імунних реакцій
JP2015536147A (ja) 2012-11-16 2015-12-21 ベス イスラエル デアコネス メディカル センター インコーポレイテッド 組換えアデノウイルスおよびその使用
EA030983B1 (ru) 2013-01-07 2018-10-31 Бет Изрейэл Диконисс Медикал Сентер, Инк. ВАКЦИНЫ, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЕ ТРИМЕРЫ ОБОЛОЧКИ (Env) ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US10248758B2 (en) 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
EP3052132B1 (en) 2013-09-30 2020-07-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
CA2941116A1 (en) 2014-02-28 2015-09-03 Janssen Vaccines & Prevention B.V. Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
CN103992396B (zh) 2014-04-17 2017-03-29 南开大学 一种潜在的高效重组HIV‑1 CRF07‑BC gp140免疫原的制备方法
US11116774B2 (en) 2014-07-11 2021-09-14 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
WO2016037154A1 (en) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use
CN112121160A (zh) 2014-09-26 2020-12-25 贝斯以色列护理医疗中心有限公司 诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
JP6887955B2 (ja) * 2015-03-18 2021-06-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 組換え体発現系のアッセイ
US20180140694A1 (en) 2015-05-04 2018-05-24 Bionor Immuno As Dosage regimen for hiv vaccine
EP3390430B1 (en) 2015-12-15 2019-08-28 Janssen Vaccines & Prevention B.V. Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
CN109219448B (zh) 2016-06-16 2022-09-20 扬森疫苗与预防公司 Hiv疫苗配制品
US10307477B2 (en) 2016-09-02 2019-06-04 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US10793607B2 (en) 2016-09-15 2020-10-06 Janssen Vaccines & Prevention B.V. Trimer stabilizing HIV envelope protein mutations
KR20200015759A (ko) 2017-06-15 2020-02-12 얀센 백신스 앤드 프리벤션 비.브이. Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법
WO2019055888A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT
US11459583B2 (en) 2017-10-31 2022-10-04 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof

Also Published As

Publication number Publication date
CA3066573A1 (en) 2018-12-20
AU2018283811A1 (en) 2020-01-02
BR112019026126A2 (pt) 2020-06-30
WO2018229711A1 (en) 2018-12-20
US11723970B2 (en) 2023-08-15
CN110958887A (zh) 2020-04-03
EP3638302A1 (en) 2020-04-22
JP7272965B2 (ja) 2023-05-12
US11229693B2 (en) 2022-01-25
MA49397A (fr) 2020-04-22
KR20200015759A (ko) 2020-02-12
JP2020527029A (ja) 2020-09-03
US20200138938A1 (en) 2020-05-07
EP3638302B1 (en) 2024-03-13
AU2018283811B2 (en) 2022-10-20
CO2019014677A2 (es) 2020-01-17
CN110958887B (zh) 2023-10-31
US20220088172A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
EA202090049A1 (ru) Поксвирусные векторы, кодирующие антигены вич, и способы их применения
EA201891415A1 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
ZA201807467B (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
EA201691611A1 (ru) Конструкции белка uspa2 и их применения
NZ729519A (en) Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin
EA201892735A1 (ru) Состав вакцины против hiv
EA201691348A1 (ru) Однофлаконные вакцинные составы
EA202091516A1 (ru) Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
EA201991377A1 (ru) Композиции универсальной вакцины против гриппа
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
CL2019000705A1 (es) Nuevos promotores.
EA202092723A1 (ru) Композиции и способы, касающиеся иммунной толерантности
EA201990711A1 (ru) Новый ehv сайт инсерции orf70
MX2019011259A (es) Adyuvante mejorado de vacuna de li.
EA201400914A1 (ru) Ротавирусная субъединичная вакцина и способы ее получения и применения
MX2018006347A (es) Proteinas de fusion fmdv y e2 y usos de ellos.
MX2019007924A (es) Vacunas contra la influenza.
EA202092164A1 (ru) Новый ehv с инактивированным ul18 и/или ul8
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
EA202090971A1 (ru) Способы применения и композиции, содержащие дулаглутид
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними